<< Back
Printer Friendly Version View printer-friendly version
BioTime Presents Retinal Restoration Data at ARVO

Demonstrates Ability to Grow Full-Thickness, 3-D Retinal Tissue

Tissue is Highly Similar to Natural Human Tissue

ALAMEDA, Calif.--(BUSINESS WIRE)--May 11, 2017-- BioTime, Inc. (NYSE MKT: BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced that a poster related to the Company’s retinal restoration technology was presented at the Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO) in Baltimore, Maryland on May 11, 2017.

BioTime scientists have grown full-thickness, 3-D retinal tissue using the Company’s proprietary pluripotent cellular platform. This tissue contains all the cell types that comprise the human retina, including RPE cells, photoreceptors and ganglion cells. Data presented at ARVO demonstrates that BioTime’s 3-D retinal tissue closely resembles young, natural human retinal tissue. The technology may ultimately be used to repair and restore sections of degenerated retinal tissue and possibly help restore visual function, irrespective of the condition that caused vision loss or blindness. Study authors conclude the Company’s 3-D retinal tissue may address the limiting factor of implementing a retinal restoration strategy to address severe retinal degenerative diseases, the availability of mutation-free retinal tissue.

“We are building a pipeline of ophthalmic therapeutics that can be efficiently manufactured in a lab,” stated Adi Mohanty, Co-Chief Executive Officer. “We are combining our regenerative medicine expertise and our pluripotent cell technology platform with current ophthalmic transplant techniques to develop therapeutics that address many degenerative diseases of the eye.”

More information about the 3-D retinal tissue study is available here.

About BioTime

BioTime, Inc. is a clinical-stage biotechnology company focused on developing and commercializing novel therapies developed from what the company believes to be the world’s premier collection of pluripotent cell assets. The foundation of BioTime’s core therapeutic technology platform is pluripotent cells that are capable of becoming any of the cell types in the human body. Pluripotent cells have potential application in many areas of medicine with large unmet patient needs, including various age-related degenerative diseases and degenerative conditions for which there presently are no cures. Unlike pharmaceuticals that require a molecular target, therapeutic strategies based on the use of pluripotent cells are generally aimed at regenerating or replacing affected cells and tissues, and therefore may have broader applicability than pharmaceutical products. BioTime also has significant equity holdings in two publicly traded companies, Asterias Biotherapeutics, Inc. and OncoCyte Corporation, which BioTime founded and which, until recently, were majority-owned consolidated subsidiaries of BioTime.

BioTime common stock is traded on the NYSE MKT and TASE under the symbol BTX. For more information, please visit www.biotimeinc.com or connect with the company on TwitterLinkedInFacebookYouTube, and Google+.

Source: BioTime, Inc.

Investor Contact:
EVC Group, Inc.
Brian Moore, 310-770-0389
bmoore@evcgroup.com
or
Media Contact:
JQA Partners, Inc.
Jules Abraham, 917-885-7378
jabraham@jqapartners.com